Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

81.550
+1.9502.45%
Volume:2.63M
Turnover:213.58M
Market Cap:24.38B
PE:-42.70
High:82.400
Open:79.500
Low:78.900
Close:79.600
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.38
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:5.21
PE(LYR):-42.70
PS:24.98

Loading ...

Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

Stock News
·
Yesterday

Keymed Bio-B Jumps Over 9% in Afternoon Trading, Company Holds Strong Competitive Edge Across Multiple Innovative Drug Areas Including Autoimmune and Oncology

Deep News
·
Sep 29

Movement Alert|KEYMED BIO-B Rises 8.48% in Regular Trading, Innovative Drug Sector Boosted by AstraZeneca USD 2 Billion Strategic Investment in Summit and Ivosdenib OS Data

Market Focus
·
Sep 29

Innovative Drug Stocks Surge Across the Board in Morning Session, with Keymed Bio-B and Akeso Both Climbing Over 9%

Deep News
·
Sep 21

Movement Alert|KEYMED BIO-B Rises 5.41% in Regular Trading, International Licensing Deal with Aeira Marks Key Milestone

Market Focus
·
Sep 21

KeyMed Bio-B Announces Departure of Non-Executive Director

Stock News
·
Sep 06

Keymed Biosciences Reports Resignation of Non-Executive Director Dr. Min Chuan Wang

Bulletin Express
·
Sep 06

Keymed Biosciences Files Board, Committee Member List with Disclosure Roles

Reuters
·
Sep 06

Keymed Biosciences Non-Executive Director Min Chuan Wang Resigns

Reuters
·
Sep 06

HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Stock News
·
Sep 03

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Reuters
·
Sep 03

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

MT Newswires
·
Sep 03

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

Reuters
·
Sep 02

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS
·
Sep 02

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS
·
Sep 02

KEYMED BIO-B: DFZQ Disposes of Shares, Long Position Falls to 4.98%

HK Disclosure
·
Sep 02

Keymed Bio-B Reports No Share Capital Changes for August 2026, Confirms Adequate Public Float

Bulletin Express
·
Sep 02

Fund Manager Trims Stake in KEYMED BIO-B With HK$3.76M Share Sale

Stock News
·
Sep 01

KEYMED BIO-B: 汇添富基金管理股份有限公司 Disposes, Long Position Falls to 4.98%

HK Disclosure
·
Sep 01

Citi Raises Keymed Bio Target Price to HK$97.5, Keeps Buy/High Risk Call

Deep News
·
Aug 23